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Over the last decade, the acceleration in the clinical use of mesenchymal stromal cells
(MSCs) has been nothing short of spectacular. Perhaps most surprising is how little we
know about the “MSC product.” Although MSCs are being delivered to patients at an
alarming rate, the regulatory requirements for MSC therapies (for example in terms of
quality assurance and quality control) are nowhere near the expectations of traditional
pharmaceuticals. That said, the standards that define a chemical compound or purified
recombinant protein cannot be applied with the same stringency to a cell-based therapy.
Biological processes are dynamic, adaptive and variable. Heterogeneity will always exist
or emerge within even the most rigorously sorted clonal cell populations. With MSCs,
perhaps more so than any other therapeutic cell, heterogeneity pervades at multiple
levels, from the sample source to the single cell. The research and clinical communities
collectively need to recognize and take steps to address this troublesome truth, to ensure
that the promise of MSC-based therapies is fulfilled.
Keywords: mesenchymal stromal cell, heterogeneity, cell subpopulations, cell-based therapy, single cell
technologies
INTRODUCTION
The term “MSCs” is used to describe a heterogeneous population of stromal cells, the exact nature
and composition of which remains the subject of much debate. They are often characterized
using criteria proposed by the International Society for Cell Therapy (ISCT) as plastic-adherent
cells, expressing a distinct set of surface antigens and with the ability to differentiate in vitro into
osteogenic, adipogenic, and chondrogenic lineages (1). This minimal definition, however, is far
from definitive. MSCs exhibit unique immunomodulatory properties, support the hematopoietic
niche and participate in tissue regeneration through diverse biological activities including
engraftment-independent paracrine signaling. Though initially described and sourced from bone
marrow we are now able to isolate MSC-like cells from a variety of tissues including adipose tissue,
dental pulp, placenta, umbilical cord, and umbilical cord blood.
Although MSCs first appeared in the clinic in 1995 (2) and have since become one of the
most clinically studied cell therapy platforms worldwide (3) many fundamental aspects of MSC
biology remain undetermined; primarily a direct consequence of the pervasive heterogeneity that
manifests itself between MSC donors, tissue sources, culture methods and individual cells within a
clonal population. Furthermore, MSCs exhibit a remarkable level of plasticity over time and when
presented with different microenvironments (4, 5). MSC multiplicity, and a lack of consensus in
the scientific community, complicates MSC characterization and their translation into the clinic.
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This review will consider the multilevel origins of heterogeneity
in MSCs (see Figure 1) and how we should be doing more
to identify, track and quantify heterogeneity in MSCs to help
determine its biological importance and impact in in vitro and
in vivo contexts.
CHANGE IS THE ONLY CONSTANT
(HERACLITUS, 535–475 BC)
MSC heterogeneity has certainly obscured our understanding of
MSC biology and, correctly, prompted calls to re-evaluate the use
of MSCs in therapy (6–10). However, the origins of heterogeneity
are complex, fascinating and a constant theme in biology. It
is clear from other work, particularly in microbial systems,
that heterogeneity arising in genetically identical populations
can have a positive impact on overall population fitness (11–
14). Stochastic fluctuations in gene expression, or “noise,” can
lead to phenotypic variability in clonal cell populations (11, 15)
and “bet hedging” can confer survival advantages on individual
cells within mixed communities when faced with environmental
change (16, 17). It has been proposed that stochastic non-
genetic variations (i.e., those not caused by genetic mutations)
contribute to the evolution of tumors using bet hedging-like
strategies (18–20) and the dynamic switching between subtly
different phenotypes has been shown to influence cell fate
in different adult and embryonic stem cell populations (21–
23). Gene expression noise in MSCs is also likely to give rise
to individual cells with different characteristics and therefore
influence the aggregate function of the population. It is also
clear that MSC heterogeneity is due at least in part to the
existence of different subpopulations with distinct expression
profiles and functional properties (24–26). It has not been
determined if discrete stromal subpopulations evolve through
stochastic or deterministic means, but many appear to possess
properties that support general tissue maintenance [for example,
immune control, vascular remodeling, hematopoiesis (25)] that
are unrelated to stem cell function. Therefore, the umbrella
“MSC” descriptor may actually cover a range of related but
distinct cell types that are yet to be fully defined.
IMPACT OF DONOR- AND
TISSUE-DEPENDENT MSC
HETEROGENEITY
Cells that currently meet this broad MSC descriptor have
been identified in virtually all post-natal organs and tissues
(27) and while bone marrow derived MSCs (BM-MSC) are
still considered the gold standard, MSCs are now frequently
also isolated from adipose tissue (AT-MSCs) and umbilical
cord or cord blood (UC/UCB-MSCs) (28–33). There are well-
documented disparities in proliferation, differentiation potential,
surface markers, transcriptional, and proteomic profile of MSCs
from different sources (34–36); an overarching consensus is
hard to come by. For example, prevailing MSC characteristics
such as tri-lineage differentiation potential present contradictory
evidence in terms of lineage preference and full tri-lineage
capacity (29, 30, 32, 37). Even when derived from the same
tissue of origin, MSCs demonstrate prodigious donor-to-donor
variation. This may be a factor of donor health influencing MSC
availability and function (38, 39). Donor age can also affect
self-renewal capacity and differentiation potential, which have
been reported to decline in older donors (40–43). However,
differences are also apparent in healthy donors of a similar
age in proliferation rate, differentiation capacity, and ultimate
clinical utility (44) leading to a further addition of complexity
when directly comparing samples. It is tempting to speculate
that MSC heterogeneity mirrors the diversity of environments
from which they may be isolated, the reality is however that our
understanding of MSCs in vivo is still in its infancy (8).
The multiplicity of MSCs and the absence of a meaningful
consensus on definitions and characterization parameters makes
comparing studies within the field difficult and translating them
into clinical practice even more so. Because heterogeneity is
seldom accounted for, and unique cell populations used in
individual research projects are rarely fully defined, many studies
are not only difficult to reproduce but difficult to evaluate for
comparability and impact within the field. Incomplete knowledge
of the characteristics of MSCs in vivo and how these will
relate to clinical outcomes further exacerbate the problem
when considering quality control requirements for MSCs as
therapeutic agents. Changes in the source materials of clinical
products, e.g., a different donor, prompt regulatory authorities
to require re-characterization and evidence of “comparability.”
In the event that comparability could not be demonstrated,
product from the original and subsequent sources would be
considered to be essentially different products. Thus, during
clinical development, data on early product iterations could
be invalidated, and post-authorization could, in the worst-case
scenario, require re-authorization. In conjunction with the need
for adequate cell numbers, this represents a major challenge to
the acceptance of cell-based therapies as mainstream treatments;
the options of extended culture or multiple donors each imply
unavoidable heterogeneity. Consequently the manufacture of
MSC products using processes that rely on a continuous supply of
new tissue donations run the significant risk of supply constraint,
interruption, and inconsistencies (10).
IN VITRO EXPANSION AND MSC
HETEROGENEITY
A typical bone marrow aspirate contains just 0.01–0.001% MSCs
(45) and trials for the regeneration of bone and cartilage tissue
commonly use in the order of 10 million cells. The need for high
levels of culture expansion adds to the challenge of generating
an MSC population that retains the ability to differentiate
effectively or secrete the appropriate biomolecules to induce
a beneficial paracrine response. Banfi et al. investigated the
growth kinetics and differentiation potential of MSCs, using
fresh isolates from different donors through to passage five,
and showed a dramatic decrease in MSC functionality over
time (46). MSCs from the same donor and same source (iliac
crest marrow aspirate) isolated at different timepoints over a
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FIGURE 1 | Sources of MSC heterogeneity; considerations for the clinical application of culture-expanded MSCs. Significant variation exists in MSC cultures isolated
from different donors and different tissue sites. Unrefined and non-standardized isolation and culture techniques do not select for homogeneous cell populations and
are likely to give rise to a mixture of stromal cell with different functions. Differences in the growth properties of MSC clones can result in cultures being dominated by
the faster-growing lines. Further levels of heterogeneity can be introduced within MSC clones through asymmetric cell division and the effects of stochastic
transcriptional noise, generating cells with modified phenotypes. MSC properties will also be determined by, for example, proximity to neighboring cells and extrinsic
signaling factors.
period of 6 months also show significant variation in growth
rates (44). Other studies have confirmed this loss of MSC
function, demonstrating reduced proliferation, colony-forming
(CFU-f) efficiency, telomere length and differentiation capacity
with increasing time in culture (4, 40, 47). With the mounting
interest in the use of MSCs for their paracrine effect it is
also noteworthy that the secreted output of MSCs has been
shown to differ with number of passages (48). This reduction
in therapeutic potency at the population level can mask changes
within clonal MSCs. Schellenberg et al. assessed MSC clones
following expansion and observed a continual decrease in CFU-
f efficiency and differentiation capacity over time (49). Earlier
analyses identified a complex hierarchy of MSC clones at varying
stages of potency (50), so it may be that the diminishing clonal
potential observed during MSC expansion is driven by subsets of
cells reaching their proliferative limit or by entering the hierarchy
of different stages through which cells pass during differentiation.
Subsequent studies to track individual clones from MSC explant
cultures showed that clonal complexity decreased markedly over
12 passages resulting in the clonal selection of a few dominant
MSC clones (51).
Given the impact that culture expansion has on MSC fate,
the in vitro environment and its influence on MSC properties
is worth considering. In the majority of research laboratories,
MSCs are expanded as a monolayer using standard tissue
culture flasks with a plasma-treated polystyrene surface and
medium containing fetal bovine serum. Surprisingly, given
the detrimental effects on MSC proliferation, differentiation
and paracrine activity of these basic methods, the industrial
expansion of MSCs for clinical applications often still retains
the same basic features (52). Scale-up can be achieved
through the use of multilayered cell culture flasks (cell
factories) or culture vessels specifically tailored for use with
closed-box and automated systems. More advanced systems
use roller bottles, hollow-fiber or stirred tank bioreactors
[reviewed by (53)]. A major problem with this approach
is that that these in vitro conditions are very different
from the in vivo MSC microenvironment, lacking much of
the complexity in terms of matrix composition, geometry,
mechanical properties and interactions with other cell types.
All of these microenvironmental factors are interpreted by the
cell and have been shown to impact upon their behavior (54–
59). At its worst, the non-physiological conditions of typical cell
cultures can cause mutations or cellular defects (60) but even
the best-case scenario results in cells whose behavior is markedly
changed. Together, this results in loss of potential from the whole
population, but MSC heterogeneity may also be driven by cells
responding to local changes in the microenvironment, such as
through poorly controlled substrate properties or local changes
in oxygen and nutrient concentration driven by the static nature
of the setup (61).
It is clear that the requirement for extended in vitro
expansion is a major contributor to the heterogeneity of MSC
populations. A deeper understanding of the impacts of different
environmental cues and the mechanisms by which they drive
change, will be integral to the development of technologies
for the large-scale production of quality MSC populations for
clinical use.
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CLINICAL EXPERIENCE AND
REGULATORY CONSIDERATIONS
RELATED TO HETEROGENEOUS CELL
THERAPY
MSC heterogeneity is multifactorial and functionally influential.
Nonetheless the clinical application of MSCs does not appear
to take this into account, with a selection of recent trial
publications suggesting a comparatively limited assessment of
cellular phenotype (Table 1). The criteria established for MSCs
by the ISCT (1) are sometimes referenced in these studies but not
necessarily met. It is of course possible that additional criteria
were specified during manufacture but not published, however
publication of more detail would increase our understanding of
the MSC phenotypes in clinical use.
Basic requirements for all biological medicines include the
necessity to define the identity, the purity and the potency of
the product. The developers of cell-based medicinal products
must define the “active substance”; the cell type on which
the therapeutic action of the product depends. Specification
limits must be established for unique identification of the
active substance within the product and for quantitation of
its purity. Other phenotypes present, for example those arising
from a tissue biopsy or culture contaminant, and non-viable
cells, are generally regarded as impurities. These impurities
should be reduced as far as possible and their content in the
finished product limited and defined by specifications. Cellular
impurities aside, major regulatory authorities do not always
require cell-based medicinal products to consist of a pure
population of cells. One of the first authorized cellular therapies
was the immunotherapy Provenge (Dendreon Inc), approved
by the US Food and Drug Administration (FDA) in 2010
for treatment of certain prostate cancers. Provenge contains
autologous peripheral blood mononuclear cells (PBMC), which
are cultured with PAP-GM-CSF, a fusion protein combining
granulocyte-macrophage colony-stimulating factor (GM-CSF)
with a prostate cancer antigen (prostatic acid phosphatase, PAP).
Antigen-presenting cells within the PBMC fraction are activated
by the fusion protein, providing a tumor-directed action. The
exact composition of the Provenge dose varies depending on
the cellular composition of each patient’s leukapheresis sample,
but may contain, amongst others, T and B lymphocytes and
natural killer cells so the therapy is inherently heterogeneous
(77, 78). In 2015 the European Union (EU) authorized its
first stem cell-based product, Holoclar (Chiesi Farmaceutici
SPA, Italy). Holoclar is a population of cultured autologous
human corneal epithelial cells containing limbal stem cells (LSCs)
intended for treatment of ocular burns. The active substance
contains only approximately 3.5% of p63bright LSCs, in a mixed
population with transient amplifying meroclones and paraclones
and terminally differentiated corneal epithelial cells (79). The
extensive heterogeneity of the overall product, which arises
from the inherent cellular variation in the patient’s biopsy, was
justified by evidence of relevant supportive properties provided
by the non-stem majority population; these were therefore not
considered to be cellular impurities (80).
In 2016, the EU approved Strimvelis [Orchard Therapeutics
(Netherlands) BV], a gene therapy for treatment of adenosine
deaminase (ADA) severe combined immunodeficiency (ADA-
SCID), in which autologous CD34+ hematopoietic stem cells
(HSCs) were transduced with ADA cDNA to provide the missing
gene sequence. The active substance of Strimvelis includes
not only the transduced CD34+ cells, but also the non-
genetically modified CD34+ fraction, based on the fact that
HSC transplantation is itself a standard treatment for ADA-
SCID (81) These examples provide illustrations of the general
acceptability, where justified, of heterogeneous cell populations
within authorized cellular therapies. In the latter two cases,
the heterogeneity specifically contributes to the overall clinical
effect of the product and is not merely a consequence of
the manufacturing process. The complexity associated with
using fundamentally variable starting materials which are then
processed, inducing further heterogeneity, implies that the purity
of most cell-based products will be challenging to define.
The regulators’ expectation of quantitation of the population
being administered in terms of identity and purity (82, 83)
will be difficult to achieve definitively; it is probably more
reasonable to demonstrate a degree of reproducibility across
product batches and to relate the composition of each batch to
those used in clinical trials than to provide exact percentages
of each minor cellular component (84). The identification of
relevant mechanisms of action will be of crucial importance in
determining the acceptability of a degree of heterogeneity, since
MSC activity in a specific clinical application should help inform
selection of an ideal MSC population, whether this may be a
heterogeneous preparation or a specified subset.
The inevitability of MSC heterogeneity and the consequences
of culture expansion for the production of cell therapies,
discussed earlier, raise key questions for developers of
regenerative medicines. Whilst, as illustrated above, there is
no obligation to demonstrate that a product contains only
the specific cell type of interest, the challenges of definition
and identification are accentuated when considering MSCs.
The apparent absence of major concerns around cellular
heterogeneity in whole organ and HSC transplantation is
sometimes highlighted as support for a less rigorous approach to
the characterization and control of cell-based therapies. However,
acceptance of heterogeneity in these situations may be due in
part to the fact that organ and HSC transplants are procedures
which are considered to fall within the practice of medicine
rather than items externally regulated as medicinal products.
FUTURE PERSPECTIVES: EMBRACING
CHANGE
In order to advance the clinical utility of MSCs, it is essential
that strategies to quantify heterogeneity are agreed. As a starting
point, it is important to define the biological properties of the
different stromal cell types within a mixed population. It is
likely that stem-cell and non-stem-cell fractions are co-extracted
using current protocols for MSC isolation. For regenerative
therapies, it would seem logical that the stem-cell component
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TABLE 1 | Sample characterization and release criteria reported in clinical trials using MSCs.
Phase Indication Tissue Source Characterization Stated release criteria Notes References
I Myocardial infarction Bone Marrow Allo Positive: CD105, CD166 limits
NS
Negative: CD45 limits NS
“Provacel”—became
Prochymal
(62)
I Crohn’s disease Bone Marrow Auto HLA II (DR), CD73, CD90, CD31,
CD34, CD45, CD80, CD105
CD73, CD90, and CD105 >90% (63)
I Graft vs. Host
Disease
Bone Marrow Allo Positive: CD73, CD90, CD105
limit NS, Negative: CD14, CD34,
CD45 limit NS
(64)
II Graft vs. Host
Disease
Bone Marrow Allo CD105, CD59, CD73, CD90,
CD31, CD34, CD14, CD45,
HLA-DR, FSP
NS (65)
II Multiple sclerosis Bone Marrow Auto CD90, CD90, CD31, CD34,
CD45
ISCT criteria Phenotypic analysis
not consistent with
ISCT
(66)
I Osteoarthritis (knee) Bone Marrow Auto Positive for CD90, CD105,
CD106, CD166, KDR (VEGFR2).
Negative for CD34, CD45,
HLA-DR
ISCT criteria Data not presented (67)
I Transplant rejection Bone Marrow Auto HLA II (DR), CD73, CD90, CD31,
CD34, CD45, CD80, CD105
CD73, CD90, CD105 >90% (68)
II Kidney
structure/function
Bone Marrow Auto HLA II (DR), CD73, CD90, CD31,
CD34, CD45, CD80, CD105
CD73, CD90, CD105 >90% Trial design, study
not reported
(69)
I Graft vs. Host
Disease
Bone Marrow Allo CD73, CD90, CD105 >80%
CD14, CD34, CD45 <10%
(70)
II Crohn’s disease Bone Marrow Allo ISCT criteria Data not presented (71)
II Multiple sclerosis Bone Marrow Auto Positive: CD90, CD73, CD44
limits NS. Negative: CD34, CD45
limits NS
(72)
II Myocardial infarction Bone Marrow Auto Positive: CD73, CD105 >90%.
Negative: CD14, CD34, CD45
<3%
(73)
I Acute Respiratory
Distress Syndrome
Bone Marrow Allo FC performed but
no data presented
(74)
I Osteoarthritis (knee) Adipose Auto CD73, CD90, CD105, CD14,
CD31, CD34, CD45, CD80, IgG1
CD14, CD45 <2% CD34<10%
CD73, CD90 >90%, CD105
>80%
(75)
I/IIa Meniscus Bone Marrow Auto Positive: CD90, CD105 >80%.
Negative: CD34, CD45 <10%
(76)
is the essential active ingredient, however non-differentiating
stromal cells could play important supporting roles, for example
in immune control; precisely why we need a full biological
understanding that relates to mechanism of action. This can
be achieved by exploiting techniques suitable for phenotyping
individual cells, including flow cytometry, electrophysiology,
microscopy (in various forms), image/morphometric analysis,
lineage tracing, and powerful new single cell-omic technologies.
Effective strategies will be required to ensure data are integrated,
interpreted correctly and shared. The key to clinical translation
will be to develop the most appropriate non-destructive
biomarker identification techniques that provide functional
discrimination. Reliable subtype-specific biomarkers will also
support the development of treatments to target MSCs in situ,
potentially negating the need for culture expansion. Alongside
these, improved methods for MSC expansion that retain, or even
promote selection of the desired MSC properties will be essential
for the production of MSC products with a more defined set of
characteristics and high therapeutic efficacy. Such technologies
will likely incorporate biophysical as well as biochemical cues
and provide platforms for scale-up culture in bioreactors. With
the role of the paracrine effect of MSCs coming to the fore
(85), therapies based on the MSC secretome or MSC-derived
extracellular vesicles (EVs) may emerge to complement the MSC
therapeutic toolkit. However, different MSC populations (or
cells within that population) are still likely to produce different
secretomes and so many of the fundamental challenges relating
to MSC heterogeneity will remain.
Given the challenges associated with providing consistency
in an MSC product from multiple tissue isolates, the generation
of MSCs from pluripotent stem cell populations has garnered
interest (86–92). The expansion capability of pluripotent cells
means that a single clonal population can potentially be
manufactured and subsequently differentiated into a virtually
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limitless supply of MSCs. This type of platform relieves the
need for continuous tissue donations, simplifies the subject of
donor-donor variation and bypasses many of the sources of MSC
heterogeneity that arise when working with ex vivo cells. Induced
pluripotent stem cells (iPSC)-derived MSCs offer the potential
for large-scale production of more homogenous, off-the-shelf
products with limited batch-to-batch variation that could deliver
more consistent clinical outcomes. The first phase I clinical trial
using iPSC-derived MSCs was completed in 2018 with promising
results from Cynata Therapeutics’s lead CymerusTMCYP-001
product for the treatment of graft vs. host disease (93), although
the full findings have not yet been published. While the clinical
use of iPSC-MSCs holds promise, an effective comparison of
pluripotent cell-derivedMSCs to their adult tissue counterparts is
required, with appropriate safety profiling. Clonal immortalized
MSC lines (both iPSC-derived and genetically modified adult
MSCs) may also be developed for bulk harvesting of secreted
products, proteins, and EV cargoes, which could ultimately
dispense with the need for the transplantation of MSCs as a
whole-cell product, however the issue of stochastic heterogeneity
arising in clonal cell populations will always persist.
MSCs can offer widespread therapeutic benefits but we must
balance enthusiastic demands for clinical progress against the
need for better mechanistic understanding. Unraveling MSC
multiplicity is the essential first step in that process.
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